NCT02757729

A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Adults With Atopic Dermatitis

Multi Center, Randomized, Double-blind, Placebo-controlled Parallel-group, Phase II Clinical Trial to Evaluate the Safety and Efficacy of PAC-14028 Cream in Mild to Moderate Atopic Dermatitis Patients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 192 (actual)
• Sponsor: Amorepacific Corporation · Industry
• Sex: All
• Age: 19 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 2 study to investigate the safety and efficacy of PAC-14028 cream in Atopic Dermatitis patients.

Detailed description

PAC-14028 Cream (0.1%, 0.3%, 1.0%) or placebo will be treated to Mild to Moderate Atopic Dermatitis patients twice daily for 8 weeks.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	PAC-14028 cream 0.1%	Topical application
DRUG	PAC-14028 cream 0.3%	Topical application
DRUG	PAC-14028 cream 1.0%	Topical application
DRUG	PAC-14028 cream vehicle	Topical application

Timeline

• Start date: 2015-10-01
• Primary completion: 2016-08-01
• First posted: 2016-05-02
• Last updated: 2016-09-20

Locations

1 site across 1 country: South Korea